Artificial intelligence analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer
Reports and Proceedings
UF mechanical engineering students 'strike gold' with their design of a device to help soldiers on the battlefield camouflage vehicles easier and faster.
European Congress 2024: New study reveals children who felt lonely for more than 6 months before the age of 12 are more likely to experience an episode of psychosis.
European Congress of Psychiatry 2024: New Scotland-wide naturalistic study shows Electroconvulsive Therapy (ECT) can reduce the severity of mental illnesses.
Concern has been on the rise that the veteran community may be at increased risk of radicalization to violent extremism. A new study finds that military veterans who expressed support for extremist groups or related beliefs on a survey said during interviews that many experienced a significant negative event during their military service. In addition, many faced difficulties transitioning to civilian life.
UC Davis Medical Center has become the first hospital in Western U.S. to perform a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter. UC Davis Medical Center has become the first hospital in Western U.S. to perform a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter.
An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.An investigational exosome-based liquid biopsy accurately detected 97% of stage 1-2 pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.